文献速递心力衰竭与心肌病心律失常

CAAN-AF试验:房颤合并心衰患者CRT联合房室结消融的随机对照研究

Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial.
PubMed 文献 · Eur Heart J · 2026-01-01

CAAN-AF为国际多中心随机对照试验,纳入143例HFrEF合并永久性房颤且已植入CRT-D的患者,1:1随机接受房室结消融(AVNA)或药物心率控制(MRCT,目标静息心率<90 bpm)。因无效提前终止,主要复合终点(全因死亡和非致死性心衰事件)无显著差异(IRR 1.16,95%CI 0.60-2.24),次要终点亦无显著差异。

要点

  • AVNA对比MRCT未降低全因死亡和非致死性心衰事件风险
  • 心血管死亡、计划外住院、需器械治疗的室性心律失常均无显著差异
  • 6分钟步行距离和SF-36生活质量评分两组间无显著差异

核心结论

  • 在永久性房颤合并HFrEF且植入CRT-D的患者中,AVNA对比MRCT未显示降低全因死亡和非致死性心衰事件。

研究设计与样本

  • CAAN-AF为国际、前瞻性、多中心、随机对照试验,因无效提前终止,共随机143例(AVNA组67例,MRCT组76例)。
  • 纳入对象为HFrEF合并永久性房颤且植入CRT-D的患者,1:1随机接受AVNA或MRCT(目标静息心率<90 bpm),所有参与者均接受器械优化。

主要发现

  • 主要复合终点(全因死亡和非致死性心衰事件)两组分别47 vs. 46起事件,IRR 1.16(95%CI 0.60-2.24),无显著差异。
  • 心血管死亡OR 1.93(95%CI 0.60-6.20),计划外住院IRR 1.01(95%CI 0.71-1.74),需器械治疗的室性心律失常IRR 0.68(95%CI 0.17-2.63),均无显著差异。
  • 6分钟步行距离和SF-36评分两组间亦无显著差异。

临床怎么用

  • 对于永久性房颤合并HFrEF且已植入CRT-D的患者,不应仅以改善CRT疗效为目的常规行房室结消融。

局限性

  • 试验因无效提前终止,最终样本量仅143例,可能不足以检出差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with heart failure with reduced ejection fraction (HFrEF) derive less benefit from cardiac resynchronization therapy (CRT) if they have coexisting atrial fibrillation (AF). Observational data suggest that atrioventricular node ablation (AVNA) may enhance CRT efficacy in this population. This trial aimed to evaluate the effect of AVNA compared with medical rate control therapy (MRCT) on CRT outcomes in patients with HFrEF and permanent AF. METHODS: The CAAN-AF trial was an international, prospective, multicentre, randomized controlled trial evaluating the impact of AVNA in patients with HFrEF, permanent AF, and CRT-defibrillators (CRT-D). Participants were randomly assigned (1:1) to AVNA or MRCT targeting a resting heart rate <90 bpm. All participants received device optimization. The primary endpoint was a composite of all-cause mortality and nonfatal heart failure events. Secondary endpoints included cardiovascular mortality, unplanned hospitalizations, ventricular arrhythmias requiring device therapy, 6-min walk distance (6MWD), and quality of life. RESULTS: With early termination of the trial due to futility, a total of 143 patients were randomized (67 to AVNA, 76 to MRCT). Baseline characteristics were similar across groups. No significant difference was found in the primary endpoint [47 vs. 46 events; incident rate ratio (IRR), 1.16; 95% confidence interval (CI), 0.60-2.24]. Secondary outcomes, including cardiovascular mortality (odds ratio, 1.93; 95% CI 0.60-6.20), unplanned hospitalizations (IRR, 1.01; 95% CI 0.71-1.74), ventricular arrhythmias requiring device therapy (IRR, 0.68; 95% CI 0.17-2.63), 6MWD, and SF-36 scores, also showed no significant differences. CONCLUSIONS: This randomized trial of patients with permanent AF and CRT-D found no evidence of a reduction in all-cause mortality and nonfatal heart failure events with AVNA compared with MRCT. TRIAL REGISTRATION: NCT01522898.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sanders P, Ariyaratnam JP, Stiles MK, et al. Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial. Eur Heart J. 2026. PMID: 41985940. doi:10.1093/eurheartj/ehag206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。